Published in Contrast Media Mol Imaging on December 28, 2006
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev (2009) 3.17
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm (2008) 1.78
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease. Proc Natl Acad Sci U S A (2008) 1.26
Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology (2007) 1.13
Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models. Neurosurgery (2008) 1.12
Cancer cell invasion: treatment and monitoring opportunities in nanomedicine. Adv Drug Deliv Rev (2011) 0.93
Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis. ACS Chem Neurosci (2011) 0.89
Cytotoxic effects and the mechanism of three types of magnetic nanoparticles on human hepatoma BEL-7402 cells. Nanoscale Res Lett (2011) 0.86
Plasma protein corona modulates the vascular wall interaction of drug carriers in a material and donor specific manner. PLoS One (2014) 0.81
Molecular magnetic resonance contrast agents for the detection of cancer: past and present. Semin Oncol (2011) 0.80
Principles and basic concepts of molecular imaging. Pediatr Radiol (2010) 0.79
Differential Impact of Plasma Proteins on the Adhesion Efficiency of Vascular-Targeted Carriers (VTCs) in Blood of Common Laboratory Animals. Bioconjug Chem (2015) 0.77
Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev (2008) 8.23
Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev (2010) 2.53
Protein-nanoparticle interactions: opportunities and challenges. Chem Rev (2011) 2.34
Toxicity of nanomaterials. Chem Soc Rev (2011) 2.07
Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging (2006) 1.97
Heterocyst differentiation and pattern formation in cyanobacteria: a chorus of signals. Mol Microbiol (2006) 1.88
Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol Imaging (2009) 1.66
Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem Rev (2010) 1.63
Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J Am Chem Soc (2007) 1.57
Ultrasmall rigid particles as multimodal probes for medical applications. Angew Chem Int Ed Engl (2011) 1.36
Relaxation induced by ferritin: a better understanding for an improved MRI iron quantification. NMR Biomed (2004) 1.33
Graphene: promises, facts, opportunities, and challenges in nanomedicine. Chem Rev (2013) 1.28
A bisphosphonate monoamide analogue of DOTA: a potential agent for bone targeting. J Am Chem Soc (2005) 1.27
Effect of nanoparticles on the cell life cycle. Chem Rev (2011) 1.19
Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell "vision" versus physicochemical properties of nanoparticles. ACS Nano (2011) 1.18
Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovasc Res (2008) 1.17
Efficient internalization of silica-coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells. Toxicol Appl Pharmacol (2011) 1.16
MRI detection of early endothelial activation in brain inflammation. Magn Reson Med (2004) 1.11
Engineered nanoparticles for biomolecular imaging. Nanoscale (2011) 1.11
The receiver domain of FrzE, a CheA-CheY fusion protein, regulates the CheA histidine kinase activity and downstream signalling to the A- and S-motility systems of Myxococcus xanthus. Mol Microbiol (2008) 1.10
Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques. Mol Pharm (2009) 1.09
Spin transition molecular materials: intelligent contrast agents for magnetic resonance imaging. J Am Chem Soc (2003) 1.08
An increase in the level of 2-oxoglutarate promotes heterocyst development in the cyanobacterium Anabaena sp. strain PCC 7120. Microbiology (2003) 1.07
Superparamagnetic nanosystems based on iron oxide nanoparticles for biomedical imaging. Nanomedicine (Lond) (2011) 1.04
Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol Imaging (2013) 1.04
Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier. Chem Rev (2012) 1.00
Protein fibrillation and nanoparticle interactions: opportunities and challenges. Nanoscale (2013) 1.00
Relaxivities of human liver and spleen ferritin. Magn Reson Imaging (2005) 0.99
Magnetic iron oxide nanoparticles for biomedical applications. Future Med Chem (2010) 0.99
Magnetic labeling of non-phagocytic adherent cells with iron oxide nanoparticles: a comprehensive study. Contrast Media Mol Imaging (2008) 0.99
A new peptidic vector for molecular imaging of apoptosis, identified by phage display technology. J Biomol Screen (2006) 0.99
Cell "vision": complementary factor of protein corona in nanotoxicology. Nanoscale (2012) 0.99
In vivo detection of inflammation using pegylated iron oxide particles targeted at E-selectin: a multimodal approach using MR imaging and EPR spectroscopy. Invest Radiol (2009) 0.97
Looking for biogenic magnetite in brain ferritin using NMR relaxometry. NMR Biomed (2005) 0.97
Hydrogels incorporating GdDOTA: towards highly efficient dual T1/T2 MRI contrast agents. Angew Chem Int Ed Engl (2012) 0.97
Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles. Nanoscale (2011) 0.96
Functionalized magnetic nanoparticles for the detection and quantitative analysis of cell surface antigen. Biomed Res Int (2012) 0.95
Anomalous nuclear magnetic relaxation of aqueous solutions of ferritin: an unprecedented first-order mechanism. Magn Reson Med (2002) 0.94
Lanthanide(III) complexes of a mono(methylphosphonate) analogue of H4dota: the influence of protonation of the phosphonate moiety on the TSAP/SAP isomer ratio and the water exchange rate. Chemistry (2005) 0.94
Ferritin-induced relaxation in tissues: an in vitro study. J Magn Reson Imaging (2004) 0.94
Magnetic resonance imaging of inflammation with a specific selectin-targeted contrast agent. Magn Reson Med (2005) 0.93
Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler Thromb Vasc Biol (2012) 0.93
End of life care in adolescents and young adults with cancer: experience of the adolescent unit of the Institut Gustave Roussy. Eur J Cancer (2011) 0.93
Reduced blood brain barrier breakdown in P-selectin deficient mice following transient ischemic stroke: a future therapeutic target for treatment of stroke. BMC Neurosci (2010) 0.93
Contrast agents: magnetic resonance. Handb Exp Pharmacol (2008) 0.92
Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics. Nanomedicine (Lond) (2011) 0.91
Dy-DTPA derivatives as relaxation agents for very high field MRI: the beneficial effect of slow water exchange on the transverse relaxivities. Magn Reson Med (2002) 0.91
Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy. J Med Chem (2008) 0.91
Magnetic targeting of surface-modified superparamagnetic iron oxide nanoparticles yields antibacterial efficacy against biofilms of gentamicin-resistant staphylococci. Acta Biomater (2012) 0.91
Impact of rigidification on relaxometric properties of a tricyclic tetraazatriacetic gadolinium chelate. Contrast Media Mol Imaging (2006) 0.91
Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer. Int J Mol Epidemiol Genet (2011) 0.90
MR molecular imaging of early endothelial activation in focal ischemia. Ann Neurol (2004) 0.90
Postamputation pain and sensory changes in treatment-naive patients: characteristics and responses to treatment with tramadol, amitriptyline, and placebo. Anesthesiology (2005) 0.89
Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis. ACS Chem Neurosci (2011) 0.89
Lanthanide(III) complexes of novel mixed carboxylic-phosphorus acid derivatives of diethylenetriamine: a step towards more efficient MRI contrast agents. Chemistry (2003) 0.89
Magnetic resonance molecular imaging of vascular cell adhesion molecule-1 expression in inflammatory lesions using a peptide-vectorized paramagnetic imaging probe. J Med Chem (2009) 0.89
Relaxation by clustered ferritin: a model for ferritin-induced relaxation in vivo. NMR Biomed (2007) 0.88
Relaxivities of paramagnetic liposomes: on the importance of the chain type and the length of the amphiphilic complex. Eur Biophys J (2008) 0.87
Big signals from small particles: regulation of cell signaling pathways by nanoparticles. Chem Rev (2013) 0.87
Paramagnetic liposomes containing amphiphilic bisamide derivatives of Gd-DTPA with aromatic side chain groups as possible contrast agents for magnetic resonance imaging. Eur Biophys J (2005) 0.87
Protein corona affects the relaxivity and MRI contrast efficiency of magnetic nanoparticles. Nanoscale (2013) 0.86
A tripodal ruthenium-gadolinium metallostar as a potential α(v)β(3) integrin specific bimodal imaging contrast agent. Inorg Chem (2012) 0.86
Lanthanide chelates containing pyridine units with potential application as contrast agents in magnetic resonance imaging. Chemistry (2004) 0.86
Polyglycerol-grafted superparamagnetic iron oxide nanoparticles: highly efficient MRI contrast agent for liver and kidney imaging and potential scaffold for cellular and molecular imaging. Contrast Media Mol Imaging (2012) 0.86
How to quantify iron in an aqueous or biological matrix: a technical note. Contrast Media Mol Imaging (2010) 0.85
Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiol Aging (2008) 0.85
Lanthanide complexes on Ag nanoparticles: designing contrast agents for magnetic resonance imaging. J Colloid Interface Sci (2009) 0.84
Hard corona composition and cellular toxicities of the graphene sheets. Colloids Surf B Biointerfaces (2013) 0.84